TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have histologically or cytologically confirmed locally advanced unresectable or metastatic transitional cell carcinoma of the urothelium (renal pelvis, ureter, urinary bladder or urethra)~* Received 1 or 2 prior treatment regimens for advanced or metastatic disease~* Confirmed radiologic disease progression during or following recent treatment~* Mandatory biopsy is required during screening~* Measurable disease per RECIST v1.1~* Adequate organ function~* ECOG 0 or 1~Exclusion Criteria:~* Prior treatment with a PARP inhibitor~* Symptomatic and/or untreated CNS metastases~* Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption of rucaparib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rucaparib (Type: EXPERIMENTAL): Oral rucaparib (monotherapy)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of RightSpot pH Indicator & RightLevel pH Detector With X-Ray Verification for FT or G-Tube Placement

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age older than 18~* Requirement for placement of a feeding tube or a G-tube replacement~* Patient or proxy able to provide informed consent~* English proficiency of person providing informed consent~Exclusion Criteria:~* Patients that are younger than the age of 18~* Inability to obtain consent~* Grossly bloody aspirate~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The study inclusion criteria is as per the label for patients with metastatic/recurrent SCCHN approved by India Health Authorities, i.e., Cetuximab is indicated for the treatment of patients with squamous cell cancer of the head and neck in combination with platinum-based chemotherapy for recurrent and/or metastatic disease.~* For each platinum-based chemotherapy, the related product labels approved by India Health Authorities will also be followed strictly in terms of patient eligibility.~Exclusion Criteria:~* Patients with known severe (grade 3 or 4; National Cancer Institute-Common Toxicity Criteria \[NCI-CTC\]) hypersensitivity reactions to Cetuximab are contraindicated for Cetuximab

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Nitrate Patch Use as Treatment of Knee AVN

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients (18-80 y.o)~* diagnosis of AVN according to MRI~Exclusion Criteria:~* Terminal illness~* Cognitive impairment / any condition disturbing informed concent.~* Nitrate intolerance~* Patients using Cyclic GMP inhibitiors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- study group (Type: EXPERIMENTAL): the patients that will get a nitrate patch
- control group (Type: PLACEBO_COMPARATOR): the patients that will get the placebo patch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Serologic evidence of chronic hepatitis C infection by anti-HCV antibody test~* Received peginterferon alfa-2a for at least 12 weeks and either did not reach a 2-log drop in HCV RNA after 12 weeks of treatment, did not reach an undetectable HCV RNA after 24 weeks of treatment, or reached undetectable HCV RNA that was detectable again at the end of 48 weeks of treatment~* Detectable serum HCV RNA at Screening~* Serologic evidence of HIV infection by HIV RNA detection~* CD4 cell count greater than or equal to (\>/=) 100 cells/mcL during therapy with peginterferon alfa-2a plus ribavirin for at least 12 weeks~* Stable HIV status and, if on antiretroviral therapy, a stable regimen for at least 6 weeks prior to Baseline~* Compensated liver disease~* No evidence of hepatocellular carcinoma~Exclusion Criteria:~* Pregnant or breastfeeding~* Antineoplastic or immunomodulatory treatment within 6 months prior to first dose~* Any investigational drug within 6 weeks prior to first dose~* Positive for hepatitis A immunoglobulin M antibody~* Severe neutropenia or thrombocytopenia at Screening while still on therapy with peginterferon alfa-2a plus ribavirin~* Severe psychiatric or neurologic comorbidity~* History of any significant medical conditions, such as immune disorders or disease of the major organ systems~* Uncontrolled thyroid disease~* Severe retinopathy~* Evidence of drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peginterferon Alfa-2a (Type: EXPERIMENTAL): Participants will receive a low dose of peginterferon alfa-2a for 18 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fecal Transplantation for Inflammatory Bowel Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Inflammatory bowel disease diagnosed at least 3 months ago~3. Failure of either one immunomodulator of at least 3 months duration, or TNF inhibitor full induction treatment, or intolerance to either of these drugs.~4. Currently active disease, partial Mayo score ≥4 for ulcerative colitis, or CDAI ≥200 for CD.~5. negative HIV , HTLV I/II, negative stool culture, Negative C diff toxin, negative CMV~Exclusion Criteria:~1. No informed consent~2. Non active inflammatory bowel disease.~3. Active infection in either the donor or the recipient,

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Fecal microbial l transplantation (Type: EXPERIMENTAL): patients with active colitis who will undergo treatment by fecal microbial transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 65 years.~* With the history of Nasopharyngeal Carcinoma and radiation therapy.~* With dysphagia occurred at least three years after radiotherapy (confirmed by videofluoroscopic swallowing study), in need of and feasible for enteral nutrition support.~* Conscious and with stable vital signs;~* Willing to participate and sign the written informed consent form either personally or by a family member.~Exclusion Criteria:~* Presence of other diseases that might cause dysphagia.~* With distant metastasis of tumors, or complicated with severe systemic disorders or malignancies.~* Concurrent participation in other treatments that could interfere with the trial.~* Inability to cooperate with treatment due to aphasia, mental health issues, etc.~* Received tube feeding for enteral nutrition support within the past three years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- The observation group (Type: EXPERIMENTAL): During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on health condition. The observation group receives IOE for enteral nutrition support
- The control group (Type: ACTIVE_COMPARATOR): During the 15-day treatment, both groups of patients are hospitalized, while conventional care and enteral nutrition support are provided to the two groups. Specifically, conventional care includes health education, dietary adjustments, nasopharyngeal hygiene, management of risk factors (blood pressure and lipid control, etc.), exercise rehabilitation, and psychological support. The frequency and content of these interventions are arranged based on health condition.The control group receives NGT for enteral nutrition support

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed adenocarcinoma of mid or low rectum~2. Locally advanced rectal cancer with one of the high-risk factors confirmed by high-resolution thin-slice Magnetic resonance image (3 mm)~   * tumors extending to within 1 mm of, or beyond the mesorectal fascia;~  * tumor extending 5 mm or more into perirectal fat;~  * resectable cT4 tumors;~  * lower third;~  * nodal involvement;~  * extramural vascular invasion~3. ECOG performance status of 0-2~4. An informed consent has been signed by the patient~Exclusion Criteria:~1. Upper rectal cancer~2. Metastatic disease~3. The patient received any previous therapy for colorectal cancer or another malignancy~4. Other malignant tumours within the last 5 years except cervical carcinoma in situ and basal cell carcinoma of the skin~5. Previous thromboembolic or haemorrhagic events within 6 months prior to registration~6. Patients with malabsorption syndrome or difficulties in swallowing~7. The patient has severe underlying diseases or poor condition to receive chemotherapy or radiotherapy~8. Pregnant of breastfeeding women~9. The patient who participate in another clinical trial, or receives any drug for the trial~10. Uncontrolled peripheral neuropathy (more than grade 2)~11. Active gastrointestinal bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: EXPERIMENTAL): Induction chemotherapy followed by chemoradiotherapy with aspirin Aspirin 100mg daily during the chemoradiotherapy
- Placebo Oral Tablet (Type: PLACEBO_COMPARATOR): Induction chemotherapy followed by chemoradiotherapy without aspirin Placebo daily during the chemoradiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Determination of the Sensitivity, Specificity & Receiver Operating Characteristic of Nerve Stimulation Receptor as a Decision-making Tool During US Guided PNB

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients, 18 years and older, undergoing regional anesthesia with a peripheral nerve block allowing a neurostimulation.~Exclusion Criteria:~* Contraindications to a peripheral nerve block~* Risk of severe intoxication to local anesthesia~* Peripheral nerve block in an area not allowing neurostimulation due to absence of motor fibers (for example, adductor canal block)~* Patient refusal~* Patient unable to communicate with the health or research team

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I - Patients undergoing regional anesthesia with a block allowing a neurostimulation. (Type: None): The investigators propose to conduct a single-blind, prospective observational study on all eligible patients undergoing regional anesthesia with a peripheral nerve block allowing a neurostimulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I/II Dose Escalation Study Using Extracranial Stereotactic Radiosurgery to Control Pain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* Prior non-hematogenous, histologically proven malignancy (specific exclusions are multiple myeloma and lymphoma)~* Pain attributable to one or two radiographically apparent metastatic lesion(s) amenable to ESRT~* Have had prior radiation to area of spine felt to be cause of patient's pain~* Zubrod performance status of 0-3~* Life expectancy of ≥ 3 months~* Signed informed consent prior to registration to study~* Radiographic evidence of stable disease outside of the spinal column for at least 6 weeks prior to study entry, as evaluated by pre-study imaging.~Exclusion Criteria:~* Women who are pregnant or nursing~* Either 'no evidence of other active cancerous disease' or 'other sites of known disease are locally controlled'~* No radiographic evidence of spinal instability (e.g. spinal cord compression requiring immediate surgical intervention)~* No initiation of chemotherapy within 15 days of trial entry.~* No plans for concomitant antineoplastic therapy (including standard fractionated RT, chemotherapy, biologic, vaccine therapy, or surgery) for at least 15 days following stereotactic radiosurgery.~* No active systemic infection.~* No evidence of myelopathy or cauda equina syndrome on clinical evaluation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group -1 (Type: EXPERIMENTAL): 1000 cGY radiation
- Group 1 (Type: EXPERIMENTAL): 1200 cGY radiation
- Group 2 (Type: EXPERIMENTAL): 1400 cGY radiation
- Group 3 (Type: EXPERIMENTAL): 1600 cGY radiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to provide informed consent, complete all study assessments and have complete medical record.~2. Age:18-75 years.~3. Histologically or cytologically confirmed diagnosis of local advanced or metastatic NSCLC.~4. Patients should be confirmed acquired EGFR T790M mutation and received osimertinib as the second line treatment, and they should have the following: (1) benefit from treatment with osimertinib initially ;(2) gradual progression on osimertinib treatment as defined by minor increment of tumor burden (≥10% but \<20% in the sum of target lesions).~5. At least one measurable lesion as defined by lesions ≥10mm in long axis according to RECIST 1.1.~Exclusion Criteria:~1. Patients who will be or were involved in any other interventional antitumour clinical studies for locally advanced/metastatic NSCLC currently or previously.~2. Small cell lung cancer (including small lung cancer mixed with non-small cell lung cancer).~3. Patients at risk of bleeding.~4. Patients with renal dysfunction.~5. Uncontrolled severe hypertension.~6. Any concomitant condition evaluated by physicians which is not suitable for osimertinib or anlotinib treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- osimertinib combined with anlotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients with informed consent, without presenting of any known contraindication for the use of Tranexamic acid and Tocilizumab.~Exclusion Criteria:~* patients or relatives who refused to consent, presenting of any known contraindication for the use of Tranexamic acid and Tocilizumab.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- SS-TG (Type: NO_INTERVENTION): Standard surgery using burr-hole procedure, irrigation and drainage.
- SS-TXA-TG (Type: ACTIVE_COMPARATOR): Standard surgery using burr-hole procedure, irrigation and drainage combined withTranexamic acid (Cyklokapron) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day until complete hematoma disappearance.
- SS-TXA-RoA (Type: ACTIVE_COMPARATOR): Standard surgery using burr-hole procedure, irrigation and drainage combined with Tranexamic acid (Cyklokapron) and Tocilizumab (RoActemra) administration. Cyklokapron tablets will be administered postoperatively in dosage 500 mg twice a day combined with RoActemra subcutaneous injection of 162 mg once a week until complete hematoma disappearance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Depression With Quetiapine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects between the ages of 18 to 75 years.~* A Structured Clinical Interview for the DSM-IV (SCID) derived diagnosis of major depression with psychosis, single or recurrent episode (unipolar or bipolar).~* Subjects may have an anxiety disorder or an additional mood disorder such as dysthymia.~* Baseline 24-item Hamilton Depression Rating Scale (HDRS) score of greater than or equal to 21.~* A baseline Positive and Negative Syndrome Scale (PANSS) score of greater than or equal to 4 on at least one of the 4 psychosis items.~* Women of childbearing potential must agree to practice a medically accepted means of contraception.~* Length of current episode no longer than 3 months.~Exclusion Criteria:~* Pregnant or lactating women~* Women of child-bearing age who refuse a pregnancy test or who refuse to use a contraceptive technique when sexually active.~* Persons with other psychotic disorders; a mood disorder due to a general medical condition or substance-induced; substance dependence disorder in the last 6 months; substance abuse in the last 6 months or a dementing disorder are excluded.~* Persons with serious, unstable medical illnesses.~* Subjects who have been intolerant or nonresponsive to adequate trials of quetiapine, haloperidol and/or citalopram.~* Subjects who have received an injectable decanoate medication within 1 half life of the medication (i.e, 4 weeks for haloperidol or 2 weeks for fluphenazine).~* Subjects who have received fluoxetine within 4 weeks prior to randomization.~* Subjects who have received aripiprazole within 2 weeks prior to randomization.~* Subjects who have been treated with ECT within the last 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues